Company profile
Perspective Therapeutics, Inc.
AMEX: CATX · Healthcare · Medical - Devices
#840 of 1,422 Healthcare companies by revenue
EA Score
46DFH 45DQ 52GM 26SS 74
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, listing tenure · ↓ operating margin, net margin
Methodology →Revenue TTM
$409.0k
Rev growth YoY (TTM)
-66.9%
Net income (FY)
-$103.1M
Employees
165
as of 2026-08-13
Market cap
$371.8M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.4M$1.4M2023
Net income-$103.1M-$103.1M2025
Operating income-$113.6M-$113.6M2025
Total assets$267.0M$267.0M2025
Liabilities$59.9M$59.9M2025
Equity$207.0M$207.0M2025
Revenue trend
FY2021 – FY2023 · USD
FY21
FY21
FY22
FY22
FY22
FY22
FY23
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Perspective Therapeutics, Inc.’s revenue?
Perspective Therapeutics, Inc. booked $1.4M in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -7191.1% net margin.
Peers · Healthcare
Glow Lifetech Corp.——American Green, Inc.51DDaxor Corporation——Braxia Scientific Corp.——Outlook Therapeutics, Inc.22DAvenue Therapeutics, Inc.25DNeighbors
King →Key facts
CEOJohan Spoor
SectorHealthcare
IndustryMedical - Devices
HeadquartersSeattle, WA
ExchangeAMEX: CATX
Employees165
IPO date2005-11-10
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.